Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trialarticle Published on 2022-02-092024-09-02 Journal: Breast Cancer Research and Treatment [Category] 대상포진, [키워드] Afatinib ErbB HER2 Metastatic breast cancer resistance [DOI] 10.1007/s10549-021-06449-4 PMC 바로가기 [Article Type] article